Cargando…
Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor
The tumor suppressor p53 responds to genotoxic and oncogenic stresses by inducing cell cycle arrest and apoptosis. Recent studies suggest that p53 also participates in the regulation of cellular immune responses. Here, we have investigated the potential of p53 gene therapy to augment immune checkpoi...
Autores principales: | Kim, Sang-Soo, Harford, Joe B., Moghe, Manish, Rait, Antonina, Chang, Esther H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169574/ https://www.ncbi.nlm.nih.gov/pubmed/30288347 http://dx.doi.org/10.1080/2162402X.2018.1484982 |
Ejemplares similares
-
Nanomedicine-Based Gene Delivery for a Truncated Tumor Suppressor RB94 Promotes Lung Cancer Immunity
por: Kim, Sang-Soo, et al.
Publicado: (2022) -
Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide
por: Kim, Sang-Soo, et al.
Publicado: (2018) -
A tumor‐targeting nanomedicine carrying the p53 gene crosses the blood–brain barrier and enhances anti‐PD‐1 immunotherapy in mouse models of glioblastoma
por: Kim, Sang‐Soo, et al.
Publicado: (2019) -
A Novel P53 Nanomedicine Reduces Immunosuppression and Augments Anti-PD-1 Therapy for Non-Small Cell Lung Cancer in Syngeneic Mouse Models
por: Kim, Sang-Soo, et al.
Publicado: (2022) -
Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance
por: Zhou, Xiaoting, et al.
Publicado: (2022)